eli LIARlilly forced to reply ..Spin doctors out on a Sunday !!!

[Guest guest]

Response to Lilly played down Zyprexa risk: N.Y. Times

----------------------------------------------------------------------

----------

http://www.healthnews-stat.com/?id=276 & keys=Eli-Lilly-Zyprexa-side-

effects

FirstCall via COMTEX News Network/ -- Eli Lilly and Company (NYSE:

LLY), in a response to a story about Zyprexa in the December 17, 2006

edition of the New York Times, adds important facts and perspectives

that were not evident in the story.

Said , M.D., Lilly's executive vice president of science

and technology, " We believe it is critical to physicians and patients

that Lilly state some important and relevant facts about our

lifesaving medication Zyprexa that are missing from the New York

Times article:

" First, contrary to incorrect statements in the Times article, Lilly

has conducted more than 23 years of research on Zyprexa. And in the

last ten years that the drug has been on the market, Lilly,

government bodies such as the National Institute of Mental Health,

and competitors -- in numerous studies that sought to show a causal

link to Zyprexa and diabetes -- have not found that Zyprexa causes

diabetes.

" Second, Zyprexa was approved by the FDA in 1996 and remains on the

market today. In that time, it has been used by more than 20 million

people worldwide, and doctors continue to prescribe it to deal with

some of the most terrible mental illnesses, such as schizophrenia and

bipolar disorder. The FDA has looked at the entire body of evidence

that Lilly has continued to provide over the years, and has affirmed

the benefit that this medicine can give to patients when accompanied

by appropriate labeling regarding benefits and risks.

" Third, from the day that Zyprexa was approved, the labeling provided

to physicians identified the potentially clinically-significant

weight gain that was observed in more than half of all patients

treated long-term with Zyprexa, as well as the diabetes-related

adverse events observed in clinical trials.

" Fourth, the Times failed to mention that these leaked documents are

a tiny fraction of the more than 11 million pages of documents

provided by Lilly as part of the litigation process. They do not

accurately portray Lilly's conduct. As part of Lilly's commitment to

patients and healthcare professionals, many high-level Lilly

physicians and researchers -- along with researchers from outside

Lilly -- were engaged for a number of years to study the issue of

Zyprexa and diabetes. Leaked documents involving these discussions do

not represent an accurate view of company strategy.

" And, finally, Lilly deplores the illegal release of select

confidential documents. Our concern is that this illegal and

selective disclosure of incomplete information will cause unwarranted

concern among patients that may cause them to stop taking their

medication without consulting a physician. This is the unfortunate

result we saw when plaintiffs' lawyers aggressively advertised about

Zyprexa in recent years while searching for clients. "

Lilly, a leading innovation-driven corporation, is developing a

growing portfolio of first-in-class and best-in-class pharmaceutical

products by applying the latest research from its own worldwide

laboratories and from collaborations with eminent scientific

organizations. Headquartered in Indianapolis, Ind., Lilly provides

answers -- through medicines and information -- for some of the

world's most urgent medical needs. Additional information about Lilly

is available at www.lilly.com.

[Guest guest]

Response to Lilly played down Zyprexa risk: N.Y. Times

----------------------------------------------------------------------

----------

http://www.healthnews-stat.com/?id=276 & keys=Eli-Lilly-Zyprexa-side-

effects

FirstCall via COMTEX News Network/ -- Eli Lilly and Company (NYSE:

LLY), in a response to a story about Zyprexa in the December 17, 2006

edition of the New York Times, adds important facts and perspectives

that were not evident in the story.

Said , M.D., Lilly's executive vice president of science

and technology, " We believe it is critical to physicians and patients

that Lilly state some important and relevant facts about our

lifesaving medication Zyprexa that are missing from the New York

Times article:

" First, contrary to incorrect statements in the Times article, Lilly

has conducted more than 23 years of research on Zyprexa. And in the

last ten years that the drug has been on the market, Lilly,

government bodies such as the National Institute of Mental Health,

and competitors -- in numerous studies that sought to show a causal

link to Zyprexa and diabetes -- have not found that Zyprexa causes

diabetes.

" Second, Zyprexa was approved by the FDA in 1996 and remains on the

market today. In that time, it has been used by more than 20 million

people worldwide, and doctors continue to prescribe it to deal with

some of the most terrible mental illnesses, such as schizophrenia and

bipolar disorder. The FDA has looked at the entire body of evidence

that Lilly has continued to provide over the years, and has affirmed

the benefit that this medicine can give to patients when accompanied

by appropriate labeling regarding benefits and risks.

" Third, from the day that Zyprexa was approved, the labeling provided

to physicians identified the potentially clinically-significant

weight gain that was observed in more than half of all patients

treated long-term with Zyprexa, as well as the diabetes-related

adverse events observed in clinical trials.

" Fourth, the Times failed to mention that these leaked documents are

a tiny fraction of the more than 11 million pages of documents

provided by Lilly as part of the litigation process. They do not

accurately portray Lilly's conduct. As part of Lilly's commitment to

patients and healthcare professionals, many high-level Lilly

physicians and researchers -- along with researchers from outside

Lilly -- were engaged for a number of years to study the issue of

Zyprexa and diabetes. Leaked documents involving these discussions do

not represent an accurate view of company strategy.

" And, finally, Lilly deplores the illegal release of select

confidential documents. Our concern is that this illegal and

selective disclosure of incomplete information will cause unwarranted

concern among patients that may cause them to stop taking their

medication without consulting a physician. This is the unfortunate

result we saw when plaintiffs' lawyers aggressively advertised about

Zyprexa in recent years while searching for clients. "

Lilly, a leading innovation-driven corporation, is developing a

growing portfolio of first-in-class and best-in-class pharmaceutical

products by applying the latest research from its own worldwide

laboratories and from collaborations with eminent scientific

organizations. Headquartered in Indianapolis, Ind., Lilly provides

answers -- through medicines and information -- for some of the

world's most urgent medical needs. Additional information about Lilly

is available at www.lilly.com.

[Guest guest]

Response to Lilly played down Zyprexa risk: N.Y. Times

----------------------------------------------------------------------

----------

http://www.healthnews-stat.com/?id=276 & keys=Eli-Lilly-Zyprexa-side-

effects

FirstCall via COMTEX News Network/ -- Eli Lilly and Company (NYSE:

LLY), in a response to a story about Zyprexa in the December 17, 2006

edition of the New York Times, adds important facts and perspectives

that were not evident in the story.

Said , M.D., Lilly's executive vice president of science

and technology, " We believe it is critical to physicians and patients

that Lilly state some important and relevant facts about our

lifesaving medication Zyprexa that are missing from the New York

Times article:

" First, contrary to incorrect statements in the Times article, Lilly

has conducted more than 23 years of research on Zyprexa. And in the

last ten years that the drug has been on the market, Lilly,

government bodies such as the National Institute of Mental Health,

and competitors -- in numerous studies that sought to show a causal

link to Zyprexa and diabetes -- have not found that Zyprexa causes

diabetes.

" Second, Zyprexa was approved by the FDA in 1996 and remains on the

market today. In that time, it has been used by more than 20 million

people worldwide, and doctors continue to prescribe it to deal with

some of the most terrible mental illnesses, such as schizophrenia and

bipolar disorder. The FDA has looked at the entire body of evidence

that Lilly has continued to provide over the years, and has affirmed

the benefit that this medicine can give to patients when accompanied

by appropriate labeling regarding benefits and risks.

" Third, from the day that Zyprexa was approved, the labeling provided

to physicians identified the potentially clinically-significant

weight gain that was observed in more than half of all patients

treated long-term with Zyprexa, as well as the diabetes-related

adverse events observed in clinical trials.

" Fourth, the Times failed to mention that these leaked documents are

a tiny fraction of the more than 11 million pages of documents

provided by Lilly as part of the litigation process. They do not

accurately portray Lilly's conduct. As part of Lilly's commitment to

patients and healthcare professionals, many high-level Lilly

physicians and researchers -- along with researchers from outside

Lilly -- were engaged for a number of years to study the issue of

Zyprexa and diabetes. Leaked documents involving these discussions do

not represent an accurate view of company strategy.

" And, finally, Lilly deplores the illegal release of select

confidential documents. Our concern is that this illegal and

selective disclosure of incomplete information will cause unwarranted

concern among patients that may cause them to stop taking their

medication without consulting a physician. This is the unfortunate

result we saw when plaintiffs' lawyers aggressively advertised about

Zyprexa in recent years while searching for clients. "

Lilly, a leading innovation-driven corporation, is developing a

growing portfolio of first-in-class and best-in-class pharmaceutical

products by applying the latest research from its own worldwide

laboratories and from collaborations with eminent scientific

organizations. Headquartered in Indianapolis, Ind., Lilly provides

answers -- through medicines and information -- for some of the

world's most urgent medical needs. Additional information about Lilly

is available at www.lilly.com.

[Guest guest]

Response to Lilly played down Zyprexa risk: N.Y. Times

----------------------------------------------------------------------

----------

http://www.healthnews-stat.com/?id=276 & keys=Eli-Lilly-Zyprexa-side-

effects

FirstCall via COMTEX News Network/ -- Eli Lilly and Company (NYSE:

LLY), in a response to a story about Zyprexa in the December 17, 2006

edition of the New York Times, adds important facts and perspectives

that were not evident in the story.

Said , M.D., Lilly's executive vice president of science

and technology, " We believe it is critical to physicians and patients

that Lilly state some important and relevant facts about our

lifesaving medication Zyprexa that are missing from the New York

Times article:

" First, contrary to incorrect statements in the Times article, Lilly

has conducted more than 23 years of research on Zyprexa. And in the

last ten years that the drug has been on the market, Lilly,

government bodies such as the National Institute of Mental Health,

and competitors -- in numerous studies that sought to show a causal

link to Zyprexa and diabetes -- have not found that Zyprexa causes

diabetes.

" Second, Zyprexa was approved by the FDA in 1996 and remains on the

market today. In that time, it has been used by more than 20 million

people worldwide, and doctors continue to prescribe it to deal with

some of the most terrible mental illnesses, such as schizophrenia and

bipolar disorder. The FDA has looked at the entire body of evidence

that Lilly has continued to provide over the years, and has affirmed

the benefit that this medicine can give to patients when accompanied

by appropriate labeling regarding benefits and risks.

" Third, from the day that Zyprexa was approved, the labeling provided

to physicians identified the potentially clinically-significant

weight gain that was observed in more than half of all patients

treated long-term with Zyprexa, as well as the diabetes-related

adverse events observed in clinical trials.

" Fourth, the Times failed to mention that these leaked documents are

a tiny fraction of the more than 11 million pages of documents

provided by Lilly as part of the litigation process. They do not

accurately portray Lilly's conduct. As part of Lilly's commitment to

patients and healthcare professionals, many high-level Lilly

physicians and researchers -- along with researchers from outside

Lilly -- were engaged for a number of years to study the issue of

Zyprexa and diabetes. Leaked documents involving these discussions do

not represent an accurate view of company strategy.

" And, finally, Lilly deplores the illegal release of select

confidential documents. Our concern is that this illegal and

selective disclosure of incomplete information will cause unwarranted

concern among patients that may cause them to stop taking their

medication without consulting a physician. This is the unfortunate

result we saw when plaintiffs' lawyers aggressively advertised about

Zyprexa in recent years while searching for clients. "

Lilly, a leading innovation-driven corporation, is developing a

growing portfolio of first-in-class and best-in-class pharmaceutical

products by applying the latest research from its own worldwide

laboratories and from collaborations with eminent scientific

organizations. Headquartered in Indianapolis, Ind., Lilly provides

answers -- through medicines and information -- for some of the

world's most urgent medical needs. Additional information about Lilly

is available at www.lilly.com.